GoodNewsoftheDay

True, recent, well-sourced good news, every morning.

HealthLarge human trial1 min read

New drug targets testosterone receptors in prostate cancer trial

Researchers tested an experimental oral medicine that destroys testosterone receptors in patients with advanced prostate cancer across three major medical institutions.

Scientists evaluated the safety and dosage of the drug. Nearly 60% of participants whose tumors held the T878/H875 mutations saw their prostate-specific antigens fall by at least half during the treatment period. This drop suggests the cancer responded well to the new medicine.

The trial showed positive signs even though many participants experienced negative side effects like nausea and fatigue during the study. Arvinas is now prioritizing a new drug with fewer side effects while a combined phase I/II trial runs until May 2027.

The findings suggest this targeted therapy can suppress cancerous activity in a small but vital subset of patients who need new options. Existing treatments often fail because cancer learns to feed on different hormones, making this receptor destruction method a promising alternative strategy.

All participants received the identical experimental medication, meaning no traditional control group was included in the experiment. A total of twenty individuals with the T878/H875 mutations showed excellent outcomes, with their condition remaining stable for an average of eleven months before progression or death occurred.

More health news

HealthLarge human trial1 min read

New weight-loss drug halves knee pain in trials

Two major clinical trials show a new weight-loss drug significantly reduces knee pain for patients with osteoarthritis.

· via ScienceDaily: Top Health

HealthLarge human trial1 min read

New pill offers hope for pancreatic cancer patients

A new drug called daraxonrasib has shown promise in reducing tumour size for people with advanced pancreatic cancer during a recent medical trial.

· via The Guardian: Science